Sponsor:
UNC Lineberger Comprehensive Cancer Center
Code:
NCT07069595
Conditions
Breast Cancer
Residual Disease
Triple Negative Breast Cancer (TNBC)
Stage II/III
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Datopotamab deruxtecan
Circulating tumor DNA (ctDNA) testing
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-11. This information was provided to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center on 2026-03-05.